REFERÊNCIAS:
1. Dohner H, et al. Acute myeloid leukemia. N Engl J Med. 2015;373(12):1136-1152
2. National Cancer Institute. Adult Acute Myeloid Leukemia Treatment (PDQ)-Patient Version. https://www.cancer.gov/types/leukemia/patient/adult-aml-treatment-pdq.
3. DiNardo C. and Cortes J. Hematology AM Soc Hematol Educ Program. 2016;(1): 348-355.
4. American Cancer Society (2020). What Is Acute Myeloid Leukemia (AML)?. https://www.cancer.org/cancer/acute-myeloid-leukemia/about/what-is-aml.html.
5. Pettit, K and Odenike, O. Defining and Treating Older Adults with Acute Myeloid Leukemia Who Are Ineligible for Intensive Therapies. Front Oncol. 2015; 5:250
6. Puty, T.C., Sarraf, J.S., Do Carmo Almeida, T.C. et al. Evaluation of the impact of single-nucleotide polymorphisms on treatment response, survival and toxicity with cytarabine and anthracyclines in patients with acute myeloid leukaemia: a systematic review protocol. Syst Rev 8, 109 (2019).
7. American Cancer Society (2020). Why People with Cancer are More Likely to Get Infections. https://www.cancer.org/treatment/treatments-and-side-effects/physical-side-effects/low-blood-counts/infections/why-people-with-cancer-are-at-risk.html.
8. American Cancer Society (2018). Typical Treatment of Most Types of Acute Myeloid Leukemia (Except Acute Promyelocytic M3). https://www.cancer.org/cancer/acute-myeloid-leukemia/treating/typical-treatment-of-aml.html.
9. Storey S, Gray T, Bryant A. Comorbidity, Physical Function, and Quality of Life in Old Adults with Acute Myeloid Leukemia. Curr Geriatr Rep. 2017;6(4): 247-254.
Material destinado exclusivamente ao público leigo.
Todos os Direitos reservados. Este material é protegido por D. Autorais e por outras Leis de proteção de propriedade intelectual. Qualquer reprodução total ou parcial, alteração, compartilhamento ou uso impróprio deste conteúdo sem autorização prévia da empresa é expressamente proibido.
Produzido e distribuído em novembro/2021. BR-ONC-210018.